مواقع ذات صلة
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
هل أنت مستخدم جديد؟ قم بالتسجيل الآن
 
دعنا نساعدك
للوصول إلى هدفك.

مقدمة

 
Since the nineteen seventies, quality of health care has become an important topic for discussion and action in the health care systems all over the world.

In every country today, the capacity of the health care system is challenged. Technological advances offer new drugs, procedures, devices and diagnostic tests that promise improved health. The global concern is how to assure the quality of care while limited resources are used wisely. An especially important challenge in the current condition of Lebanon's health care is to carry out an evaluation of both the health status of the people and the functioning of health care services.

Most countries have nowadays some action going in the ever-expanding field of healthcare quality improvement. One approach that is gaining acceptance around the world is accreditation. Besides its basic purpose of assessing hospitals' compliance with standards, it could play an educative, consultative and informative role, and act as a bridge between the various stakeholders that provides a platform for continued dialogue.

As part of the health reform agenda, the Ministry of Public Health has taken the initiative to address quality management in all its dimensions by driving and supporting the establishment of an accreditation system for hospitals.

To this end, a consultant, Overseas Projects Corporation of Victoria (Australia), was contracted to complete an accreditation manual for acute hospitals in Lebanon. The Health Sector Rehabilitation Project, financed by a loan from the World Bank, supported and supervised this project.
The Manual has been locally developed with the pilot survey hospitals and other major stakeholders, and serves as the first step in the evolution of hospital accreditation in Lebanon. It is expected that all hospitals will be surveyed against the Manual in 2001-2002.

I commend this first edition of the Manual to all acute hospitals, as it signals the way ahead for the accreditation of hospitals, based on quality assurance and quality improvement in patient care.

This language of health care quality measurement and improvement will be continuously refined, improved and updated. Therefore, it is anticipated that the Manual will be reviewed on a regular basis to reflect the further development of Standards.
Accreditation Standards are always a "work in progress". In this spirit, we welcome constructive suggestions on their modification and improvement.

Quality cannot be an accident; it is always the result of high intentions, sincere effort, intelligent direction and skillful execution. It represents the wise choice of many alternatives.

Providers and professionals in health care are the natural partners in quality improvement. Through accreditation, we can combine our efforts, in an innovative partnership, towards the achievement of a better health status for our people.
 
 
Dr. Walid Ammar
 
Director General,
 
Ministry of Public Health,
 
Lebanon
    3
    ...
التصنيف العلاجي الاسم أساسي / جنيسي التركيبة العلمية العيار الشكل الصيدلاني سعر المبيع من العموم
V03AE02 RENVELA B Sevelamer - 800mg 800mg Tablet, film coated 8,386,876 L.L
C01EB18 RANEXA B Ranolazine - 375mg 375mg Tablet, prolonged release 3,985,837 L.L
C01EB18 RANEXA B Ranolazine - 500mg 500mg Tablet, prolonged release 3,985,837 L.L
C01EB18 RANEXA B Ranolazine - 750mg 750mg Tablet, prolonged release 3,985,837 L.L
J06BB01 RHOPHYLAC 300 BioHuman Human anti-D (rh) immunoglobulin - 300mcg/2ml 300mcg/2ml Injectable solution 5,939,784 L.L
J06BB01 RHESONATIV BioHuman Human anti-D (rh) immunoglobulin - 625IU/ml 625IU/ml Injectable solution 12,281,758 L.L
J06BB05 RABISHIELD-100 (RABIES HUMAN MONOCLONAL ANTIBODY rDNA) BioHuman Rabies, Human IgG1 Monoclonal Antibody - 100IU/2.5ml 100IU/2.5ml 8,455,824 L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution L.L
L03AB07 REBIF BioTech Interferon beta-1a - 44mcg/0.5ml 12MIU Injectable solution 82,479,505 L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution 15,147,973 L.L
B02BD02 RECOFACT VIII BioTech Moroctocog alfa - 500IU 500IU Injectable powder for solution+diluent 12,049,005 L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 500IU 500IU Injectable powder for solution+solvent 76,080,435 L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 1000IU 1000IU Injectable powder for solution+solvent 149,006,276 L.L
B02BD04 REFIXIA BioTech Nonacog beta pegol (factor IX) - 2000IU 2000IU Injectable powder for solution+solvent 298,171,406 L.L
B02BD08 RECOFACT VII BioTech Eptacog alfa (activated) recombinant - 1.2mg 1.2mg Injectable powder for solution+diluent 47,533,131 L.L
J07BG01 RABIVAX-S (RABIES VACCINE INACTIVATED) BioTech Freeze dried inactivated purified rabies antigen (Pitman Moore PM3218 as virus strain) - Injectable freeze dried material 1,552,138 L.L
J07BH01 ROTASIIL, ROTAVIRUS VACCINE, LIVE ATTENUATED (ORAL FREEZE-DRIED) BioTech Rotavirus bovine-human , live attenuated - Suspension 2,822,069 L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg 100mg/10ml Injectable concentrated solution L.L
J07BH01 ROTASIIL, ROTAVIRUS VACCINE, LIVE ATTENUATED (ORAL LIQUID) BioTech Rotavirus bovine-human , live attenuated - Liquid 2,822,069 L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg 500mg/10ml Injectable concentrated solution L.L
L03AB07 REBIF BioTech Interferon beta-1a - 44mcg/0.5ml 12MIU Injectable solution L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg 100mg/10ml Injectable concentrated solution 11,708,063 L.L
L01FA01 RIXATHON BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 28,438,096 L.L
L01FA01 RUXIENCE BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 13,157,756 L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg 500mg/50ml Injectable concentrated solution 45,258,360 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 66,951,899 L.L
A10AD06 RYZODEG BioTech Insulin degludec - 70%, Insulin aspart - 30% 100IU/ml Injectable solution 7,058,661 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 116,417,745 L.L
L01FA01 RUXIENCE BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 59,148,151 L.L
L04AB02 REMICADE BioTech Infliximab - 100mg 100mg Injectable concentrated powder for solution 30,111,023 L.L
    3
    ...
Sitemap
حقوق الطبع والنشر محفوظة ل وزارة الصحة العامة ©2025